Price (delayed)
$1.82
Market cap
$276.04M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.3
Enterprise value
$436.36M
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs. Heron
There are no recent dividends present for HRTX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.